Analysis: Chinese pharma giant facing US ban may redirect investment to Ireland

Companies part of the WuXi group that face restrictions by US lawmakers have invested more than €500 million into Ireland in the past five years

Market analysts have warned that firms such as WuXi now face an uncertain future in the US market as the laws would not only ban federal agencies from doing business with WuXi